Dynamics of progenitor cells and ventricular assist device intervention.
Experimental and clinical evidence suggests that a heterogeneous group of bone-marrow-derived circulating progenitor cells, with variations in phenotype and function, provide an endogenous repair mechanism, contributing to vascular healing and remodeling under physiological and pathological conditions, such as cancer, atherosclerosis, myocardial infarction, and end-stage heart failure. Implantation of ventricular assist devices (VADs) for circulatory support is indicated in selected patients with end-stage heart failure as a bridge to heart transplantation, however seldom; improvement of ventricular contractility has been well documented with prolonged cardiac unloading. The current review summarizes recent findings from in vitro and in vivo studies, focusing on the biological features and the possible role of progenitor cells in the transient myocardial recovery, occasionally seen after VAD implantation, and speculates on their clinical utilities for the treatment of the failing human heart.
Tsiavou
Anastasia
A
A' Department Cardiology, Onassis Cardiac Surgery Center, 356 Syngrou Ave, Athens, Kallithea, 17674, Greece.
Manginas
Athanassios
A
D000818:Animals; D002465:Cell Movement; D042783:Endothelial Cells / Q000276:immunology / Q000473:pathology*; D006333:Heart Failure / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D006353:Heart-Assist Devices; D006801:Humans; D009200:Myocardial Contraction; D009206:Myocardium / Q000276:immunology / Q000473:pathology*; D010641:Phenotype; D020127:Recovery of Function; D012038:Regeneration; D013234:Stem Cells / Q000276:immunology / Q000473:pathology*; D013997:Time Factors; D016896:Treatment Outcome